EAGAN, Minn., Sept. 7, 2017 /PRNewswire-USNewswire/ -- Today, St. Teresa Medical, Inc® and Orb Orthopedics Ltd. in Auckland New Zealand, which is St. Teresa Medical's exclusive distributor, announced the first commercial use of its novel hemostatic fibrin-based surgical dressing – SURGICLOT®. Dr. John Ferguson, an internationally renowned spine surgeon from Auckland, New Zealand was the first surgeon to use SURGICLOT® commercially. Dr. Ferguson was performing an elective two-level posterior lumbar spine fusion on a patient at Ascot Hospital in Auckland. Upon completion of the surgery, Dr. Ferguson made the following observations on SURGICLOT® and its successful clinical usage in this procedure.
Dr. Ferguson reports:
"I have now had the opportunity to use St Teresa's SURGICLOT®product in both the animal model and in the treatment of patients undergoing spine surgery. I have been impressed with its handling characteristics and its efficacy. Epidural bleeding was stopped rapidly and permanently. Once the epidural bleeding had been controlled it was once again possible to mobilize the dura without restarting the bleeding. Perhaps most important is the knowledge that the product does not swell and therefore can be left within the surgical field if necessary. I have also had the opportunity to use the product in the animal model looking at both arterial and venous injuries. It was possible to control arterial bleeds with little difficulty, making tricky surgical situations such as a tear to the back side of the iliac vessels in the setting of anterior lumbar interbody fusion or segmental vessels in the setting of direct lateral approaches, reconstructions and fusions safer and easier to control."
About St. Teresa
St. Teresa Medical, Inc.®, based in Eagan, Minnesota., is a biomedical-device company developing a unique dissolvable hemostatic dressing called SURGICLOT® for use in treating cancellous bone bleeding. SURGICLOT® is fabricated from electro-spun dextran nano-fibers infused with human-sourced fibrinogen and thrombin. SURGICLOT® is the only blood-clotting technology with a rapidly dissolvable delivery mechanism, enhancing the body's natural clotting mechanism. The dextran nano-fibers dissolve within seconds in contact with bodily fluids. Upon dissolving, the thrombin acts on the fibrinogen and converts it to fibrin which forms a natural clot at the injury site which stops bleeding.
For more information, see www.StTeresaMedical.com. For more information, contact Brian Jackson, CFO at 651-789-4633.
SOURCE St. Teresa Medical, Inc.